Helicobacter Pylori Eradication for Peptic Ulceration: An Observational Study in a Scottish Primary Care Setting

• Published in: Scottish medical journal 2002-04, Vol.47 (2), p.28-33
• Main Authors: Forrest, E. H., MacKenzie, J. F., Stuart, R. C., Morris, A. J.
• Format: Article
• Language: English
• Subjects: Eradication; Female; Helicobacter Infections - drug therapy; Helicobacter pylori; Histamine H2 Antagonists - therapeutic use; Humans; Male; Middle Aged; Patients; Peptic Ulcer - microbiology; Peptic ulcers; Practice Patterns, Physicians; Primary Health Care; Proton Pump Inhibitors; Scotland
• ISSN: 0036-9330; 2045-6441
• DOI: 10.1177/003693300204700202

Despite being established for the treatment of peptic ulcer (PU) disease, few studies have assessed the long-term effectiveness and economic benefits of Helicobacter pylori (Hp) eradication in primary care. Our aim was to investigate the effect of community based Hp eradication for patients with chronic peptic ulcer disease requiring maintenance acid suppression. The endpoints used were the patient s dyspeptic symptoms and the requirement for the prescription of maintenance acid suppression therapy. The study area covered seven general practices in the Glasgow area. Patients with previously diagnosed peptic ulcer disease receiving prescribed acid suppression therapy were invited to a dyspepsia clinic. Hp status was assessed by Helisal rapid blood test (HRBT). Positive patients received Hp eradication therapy and were reviewed six weeks later. At six months a review of practice records was carried out, and two years after eradication a postal questionnaire was sent to participating patients. A total of 243 patients attended the initial clinic of which 81.9% were HRBT positive. 156 of 196 patients offered Hp eradication re-attended at six weeks. The per protocol eradication rate was 91.7%. After six months patients who had received eradication therapy were less likely to require maintenance acid suppression therapy compared with those to whom eradication was not given. Two years after treatment 76.5% of patients felt their symptoms were improved, but 42.2% were still receiving maintenance therapy. The estimated cost of treatment per month per patient had fallen from £20.23 to £9.39 after eradication. In conclusion we felt that community based Hp eradication for patients with chronic PU disease is effective, however it does not completely alleviate dyspepsia. Predictors of symptomatic response or of no longer requiring acid suppression therapy after two years were younger age of onset of PU disease and absence of pre-documented gastro-oesophageal reflux disease or hiatus hernia. Hp eradication improves patient s symptoms, reduces the requirement for maintenance acid suppression and is cost-effective after two years follow-up in this targeted group.